Analysts See $-1.05 EPS for Insmed Incorporated (INSM)

September 30, 2018 - By Jack Shaw

Insmed Incorporated (NASDAQ:INSM) LogoInvestors sentiment decreased to 1.2 in 2018 Q2. Its down 0.26, from 1.46 in 2018Q1. It dived, as 19 investors sold Insmed Incorporated shares while 31 reduced holdings. 21 funds opened positions while 39 raised stakes. 78.27 million shares or 0.94% more from 77.55 million shares in 2018Q1 were reported.
Cubist Systematic Strategies Ltd Liability Co owns 8,468 shares for 0.01% of their portfolio. Foresite Cap Ii Ltd Liability has invested 8.06% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Moreover, Sei has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 14,196 shares. First Manhattan accumulated 25 shares or 0% of the stock. 607 were reported by Royal Bank Of Canada. Weiss Multi, Alabama-based fund reported 78,000 shares. California State Teachers Retirement Systems holds 117,199 shares. Emerald Mutual Fund Advisers Trust invested in 0.54% or 630,115 shares. Morgan Stanley accumulated 705,283 shares. Citadel Advsr Lc holds 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 222,388 shares. Oberweis Asset holds 0.06% of its portfolio in Insmed Incorporated (NASDAQ:INSM) for 10,600 shares. Mackay Shields Limited Liability Corporation invested in 28,908 shares. Sabby Mngmt Lc holds 17,800 shares. Earnest Prtn Ltd Limited Liability Company holds 0% in Insmed Incorporated (NASDAQ:INSM) or 1,130 shares. Jpmorgan Chase And holds 0% or 264,470 shares.

Since May 29, 2018, it had 0 insider buys, and 1 insider sale for $1.05 million activity.

Analysts expect Insmed Incorporated (NASDAQ:INSM) to report $-1.05 EPS on November, 1.They anticipate $0.36 EPS change or 52.17 % from last quarter’s $-0.69 EPS. After having $-1.00 EPS previously, Insmed Incorporated’s analysts see 5.00 % EPS growth. The stock decreased 5.25% or $1.12 during the last trading session, reaching $20.22. About 1.92M shares traded or 120.37% up from the average. Insmed Incorporated (NASDAQ:INSM) has declined 36.77% since September 30, 2017 and is downtrending. It has underperformed by 52.39% the S&P500.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 5 analysts covering Insmed (NASDAQ:INSM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Insmed had 5 analyst reports since April 23, 2018 according to SRatingsIntel. The rating was maintained by Morgan Stanley with “Overweight” on Monday, August 6. The rating was downgraded by JMP Securities to “Market Perform” on Monday, August 6. The stock of Insmed Incorporated (NASDAQ:INSM) has “Outperform” rating given on Monday, April 23 by Credit Suisse. H.C. Wainwright maintained Insmed Incorporated (NASDAQ:INSM) on Thursday, June 7 with “Buy” rating.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.56 billion. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: which released: “The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares” on September 18, 2018, also with their article: “The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results” published on September 28, 2018, published: “Key events next week – healthcare” on September 21, 2018. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: and their article: “Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only …” published on September 28, 2018 as well as‘s news article titled: “The Week Ahead: Nike Earnings, FDA Debates E-Cig Industry, SurveyMonkey IPOs” with publication date: September 24, 2018.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: